Full Name
Jay Tiesman Ph.D.
Job Title
Genomics Group Lead
Company
Procter & Gamble
Speaker Bio
Dr. Jay Tiesman is a Research Fellow in the Global BioScience Division of The Procter & Gamble Company in Cincinnati, Ohio, USA. He is the Genomics Group Leader and, since joining P&G in 1993, has been actively involved in developing genomics and metagenomics capabilities within the Company. He has been particularly interested in the use of these platforms to gain insight into epithelial cell biology. Before joining P&G, he completed postdoctoral training in the laboratory of Dr. Charlie Hart at ZymoGenetics, Inc. in Seattle, Washington. At ZymoGenetics, he pursued research in the field of growth factor signal transduction associated with wound healing and tissue remodeling. He obtained his Ph.D. in Pathology from the University of Nebraska Medical Center in Omaha, Nebraska. In Omaha, he worked in the Laboratory of Dr. Angie Rizzino at the Eppley Cancer Institute, delineating the roles and impact of growth factors on embryonic development. Before joining Dr. Rizzino, he obtained Bachelor degrees in Philosophy and Biology at Creighton University in Omaha.
Dr. Tiesman is an acknowledged expert in genomics and microbiome experimental design and has published over 50 articles and book chapters, two of which have earned “Publication of the Year” honors and one of which has earned recognition from the Faculty of 1000. He also speaks extensively at international meetings on the topic of transcriptomics experimental design and is listed on over 130 presentations. He collaborates broadly with scientists in academia and the biotechnology industry and has been a member of many academic/governmental/industrial organizations and scientific advisory boards. He most recently served as adjunct professor at The Hong Kong Polytechnic University and currently sits on the Board of Managers of Ischemia Care Diagnostics LLC.
Dr. Tiesman is an acknowledged expert in genomics and microbiome experimental design and has published over 50 articles and book chapters, two of which have earned “Publication of the Year” honors and one of which has earned recognition from the Faculty of 1000. He also speaks extensively at international meetings on the topic of transcriptomics experimental design and is listed on over 130 presentations. He collaborates broadly with scientists in academia and the biotechnology industry and has been a member of many academic/governmental/industrial organizations and scientific advisory boards. He most recently served as adjunct professor at The Hong Kong Polytechnic University and currently sits on the Board of Managers of Ischemia Care Diagnostics LLC.
Speaking At